NO2025013I1 - concizumab - Google Patents

concizumab

Info

Publication number: NO2025013I1
Authority: NO; Norway
Prior art keywords: concizumab
Prior art date: 2008-12-22

Application number

NO2025013C

Other languages

English (en)

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-22

Filing date

2025-02-25

Publication date

2025-02-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40639722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2025013(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2025-02-25 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2025-02-25 Publication of NO2025013I1 publication Critical patent/NO2025013I1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Microbiology (AREA)
Zoology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO2025013C 2008-12-22 2025-02-25 concizumab NO2025013I1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP08172520		2008-12-22
PCT/EP2009/067598 WO2010072691A1 (en)	2008-12-22	2009-12-18	Antibodies against tissue factor pathway inhibitor

Publications (1)

Publication Number	Publication Date
NO2025013I1 true NO2025013I1 (no)	2025-02-25

Family

ID=40639722

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO2025013C NO2025013I1 (no)	2008-12-22	2025-02-25	concizumab

Country Status (23)

Country	Link
US (5)	US8361469B2 (no)
EP (3)	EP3260466A1 (no)
JP (2)	JP5714505B2 (no)
KR (2)	KR101600308B1 (no)
CN (1)	CN102325795B (no)
AU (1)	AU2009331570C1 (no)
BR (1)	BRPI0924058B1 (no)
CA (1)	CA2745317C (no)
DK (1)	DK2379600T4 (no)
ES (1)	ES2458665T5 (no)
FI (1)	FIC20250014I1 (no)
FR (2)	FR24C1008I1 (no)
HU (1)	HUS2500017I1 (no)
IL (1)	IL213356A (no)
MX (1)	MX2011006501A (no)
NL (1)	NL301310I2 (no)
NO (1)	NO2025013I1 (no)
PL (1)	PL2379600T5 (no)
PT (1)	PT2379600E (no)
RU (1)	RU2562114C2 (no)
TW (1)	TWI476003B (no)
WO (1)	WO2010072691A1 (no)
ZA (1)	ZA201104599B (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2728685A1 (en)	2008-06-30	2010-01-07	Novo Nordisk A/S	Anti-human interleukin-20 antibodies
UA112050C2 (uk) *	2008-08-04	2016-07-25	БАЄР ХЕЛСКЕР ЛЛСі	Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
BRPI0924058B1 (pt)	2008-12-22	2021-08-17	Novo Nordisk A/S	Anticorpos monoclonais, seus usos, bem como composição farmacêutica
US8454956B2 (en)	2009-08-31	2013-06-04	National Cheng Kung University	Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
AU2011219715B2 (en) *	2010-02-26	2014-12-11	Novo Nordisk A/S	Stable antibody containing compositions
ES2765418T3 (es)	2010-03-01	2020-06-09	Bayer Healthcare Llc	Anticuerpos monoclonales optimizados contra el inhibidor de la ruta del factor tisular (TFPI)
JP6294075B2 (ja)	2010-05-28	2018-03-14	ノヴォノルディスクアー／エス	抗体及び防腐剤を含む安定した多用量組成物
US9228022B2 (en)	2010-06-30	2016-01-05	Novo Nordisk A/S	Antibodies that are capable of specifically binding tissue factor pathway inhibitor
TW201212938A (en)	2010-06-30	2012-04-01	Novo Nordisk As	Antibodies that are capable of specifically binding tissue factor pathway inhibitor
MY190951A (en) *	2011-04-01	2022-05-24	Bayer Healthcare Llc	Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2014015133A1 (en)	2012-07-19	2014-01-23	National Cheng Kung University	Treatment of osteoarthritis using il-20 antagonists
US8603470B1 (en)	2012-08-07	2013-12-10	National Cheng Kung University	Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en)	2012-08-07	2014-10-07	National Cheng Kung University	Treating allergic airway disorders using anti-IL-20 receptor antibodies
US9592297B2 (en)	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
ES2657304T3 (es) *	2013-03-15	2018-03-02	Bayer Healthcare Llc	Variantes de anticuerpo anti TFPI con unión diferencial a lo largo del intervalo de pH para mejorar la farmacocinética
CN105209497B (zh) *	2013-03-15	2021-09-07	诺和诺德股份有限公司	能够特异性结合组织因子途径抑制物上的两个表位的抗体
TW201522368A (zh) *	2013-03-15	2015-06-16	Bayer Healthcare Llc	抗組織因子路徑抑制劑之前藥抗體
WO2015007880A1 (en) *	2013-07-19	2015-01-22	Novo Nordisk A/S	Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
CN106659909B (zh)	2013-08-21	2022-01-11	德克萨斯州大学系统董事会	用于靶向连接蛋白半通道的组合物和方法
SG10201804945WA (en) *	2013-12-12	2018-07-30	Shanghai hengrui pharmaceutical co ltd	Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
MD20160130A2 (ro) *	2014-04-27	2017-04-30	Ccam Biotherapeutics Ltd.	Anticorpi umanizaţi contra CEACAM1
US11279771B2 (en)	2014-09-17	2022-03-22	Novo Nordisk A/S	Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)
AU2015384281B2 (en) *	2015-02-25	2018-11-22	Mogam Institute For Biomedical Research	Novel antibody binding to TFPI and composition comprising the same
KR20230074843A (ko) *	2015-08-19	2023-05-31	화이자 인코포레이티드	조직 인자 경로 억제제 항체 및 그의 용도
CA3015839A1 (en)	2016-02-26	2017-08-31	The Board Of Regents Of The University Of Texas System	Connexin (cx)43 hemichannel-binding antibodies and uses thereof
TWI787230B (zh)	2017-01-20	2022-12-21	法商賽諾菲公司	抗ＴＧＦ-β抗體及其用途
AR110755A1 (es)	2017-01-20	2019-05-02	Genzyme Corp	Anticuerpos dirigidos a hueso
JP7094722B2 (ja) *	2018-02-28	2022-07-04	キヤノン株式会社	画像読取装置及び画像形成装置
KR102337683B1 (ko) *	2018-09-21	2021-12-13	주식회사 녹십자	고효율 항-tfpi 항체 조성물
KR20240135884A (ko) *	2018-10-11	2024-09-12	화이자 인코포레이티드	Tfpi 길항제의 투여량 섭생법
WO2021015237A1 (ja) *	2019-07-24	2021-01-28	国立研究開発法人科学技術振興機構	抗体酵素の革新的製造技術
CN112442127A (zh) *	2019-08-29	2021-03-05	苏州康宁杰瑞生物科技有限公司	针对tfpi的单克隆抗体
EP4058061A1 (en) *	2019-11-13	2022-09-21	Pfizer Inc.	Stable aqueous anti-tfpi antibody formulation
JP7807081B2 (ja) *	2020-07-02	2026-01-27	北京拓界生物医薬科技有限公司	抗ＦＸＩ／ＦＸＩａ抗体、その抗原結合断片と医薬用途
US20230357432A1 (en)	2020-09-24	2023-11-09	Novo Nordisk Health A/S	Pharmaceutical formulation of concizumab and method of production thereof
CN116136537A (zh) *	2021-11-16	2023-05-19	北京积水潭医院	组织因子途径抑制物抗凝活性的检测方法和试剂盒及其应用
CN118613492A (zh) *	2022-01-30	2024-09-06	西湖大学	Tfpi结合多肽及其用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4966852A (en) *	1987-07-23	1990-10-30	Monsanto Company	DNA clone of human tissue factor inhibitor
US5677425A (en)	1987-09-04	1997-10-14	Celltech Therapeutics Limited	Recombinant antibody
DK261490D0 (da) *	1990-10-31	1990-10-31	Novo Nordisk As	New pharmaceutical compound
EP0539975A1 (en) †	1991-10-31	1993-05-05	Teijin Limited	Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor
JPH06153985A (ja) *	1992-11-16	1994-06-03	Teijin Ltd	モノクローナル抗体
JPH06153981A (ja)	1992-11-30	1994-06-03	Teijin Ltd	Ｌａｃｉの免疫学的測定方法、それに用いるキット並びにモノクローナル抗体
US5455338A (en) *	1993-11-05	1995-10-03	Zymogenetics, Inc.	DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5589359A (en)	1994-08-05	1996-12-31	Chiron Corporation	Chimeric proteins
JPH0875736A (ja)	1994-09-06	1996-03-22	Chemo Sero Therapeut Res Inst	ヒト組織因子凝固系インヒビターの定量法
US5902582A (en) *	1995-09-05	1999-05-11	Chiron Corporation	Use of TFPI inhibitor for treatment of cancer
JP3681206B2 (ja)	1995-12-26	2005-08-10	株式会社三菱化学ヤトロン	抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
JP2002505574A (ja)	1997-04-30	2002-02-19	エンゾン，インコーポレイテッド	ポリアルキレンオキシド修飾された単鎖ポリペプチド
ATE474854T1 (de) *	2000-01-27	2010-08-15	Medimmune Llc	Rsv neutralisierende antikörper mit sehr hohen affinität
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
JP2007534631A (ja)	2003-10-28	2007-11-29	ノボ　ノルディスク　アクティーゼルスカブ	ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
US7585842B2 (en)	2004-04-16	2009-09-08	The Reagents Of The University Of California	Human kunitz-type inhibitor with enhanced antifibrinolytic activity
US7015746B1 (en) *	2004-05-06	2006-03-21	National Semiconductor Corporation	Bootstrapped bias mixer with soft start POR
JP2008531692A (ja) †	2005-03-04	2008-08-14	ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ	凝固及び線維素溶解カスケードのモジュレーター
UA112050C2 (uk) *	2008-08-04	2016-07-25	БАЄР ХЕЛСКЕР ЛЛСі	Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
KR101792032B1 (ko) *	2008-12-19	2017-11-02	백스터 인터내셔널 인코포레이티드	Ｔｆｐｉ 억제제 및 사용 방법
EP2379599B1 (en) *	2008-12-22	2015-09-02	Novo Nordisk A/S	Antibodies against tissue factor pathway inhibitor (tfpi)
BRPI0924058B1 (pt)	2008-12-22	2021-08-17	Novo Nordisk A/S	Anticorpos monoclonais, seus usos, bem como composição farmacêutica
US8965454B2 (en)	2009-03-04	2015-02-24	Andrew Llc	Amplifier system for cell sites and other suitable applications
US8598327B2 (en)	2009-08-18	2013-12-03	Baxter International Inc.	Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
EP2467167B1 (en)	2009-08-18	2017-08-16	Baxalta GmbH	Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
ES2765418T3 (es) *	2010-03-01	2020-06-09	Bayer Healthcare Llc	Anticuerpos monoclonales optimizados contra el inhibidor de la ruta del factor tisular (TFPI)
US8598008B2 (en) †	2010-10-20	2013-12-03	Texas Instruments Incorporated	Stacked ESD clamp with reduced variation in clamp voltage
CA2827160A1 (en) †	2011-02-11	2012-08-16	Baxter Healthcare S.A.	Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
MY190951A (en) †	2011-04-01	2022-05-24	Bayer Healthcare Llc	Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
EP2827910A2 (en) †	2012-03-22	2015-01-28	Baxter International Inc	Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
CN105209497B (zh)	2013-03-15	2021-09-07	诺和诺德股份有限公司	能够特异性结合组织因子途径抑制物上的两个表位的抗体
AU2015384281B2 (en) †	2015-02-25	2018-11-22	Mogam Institute For Biomedical Research	Novel antibody binding to TFPI and composition comprising the same
KR20230074843A (ko) †	2015-08-19	2023-05-31	화이자 인코포레이티드	조직 인자 경로 억제제 항체 및 그의 용도

2009
- 2009-12-18 BR BRPI0924058-6A patent/BRPI0924058B1/pt active IP Right Grant
- 2009-12-18 KR KR1020117016958A patent/KR101600308B1/ko active Active
- 2009-12-18 EP EP17176891.4A patent/EP3260466A1/en not_active Withdrawn
- 2009-12-18 EP EP14151704.5A patent/EP2746294A3/en not_active Withdrawn
- 2009-12-18 AU AU2009331570A patent/AU2009331570C1/en active Active
- 2009-12-18 EP EP09793543.1A patent/EP2379600B2/en active Active
- 2009-12-18 CA CA2745317A patent/CA2745317C/en active Active
- 2009-12-18 KR KR1020167005204A patent/KR101745394B1/ko active Active
- 2009-12-18 JP JP2011541494A patent/JP5714505B2/ja active Active
- 2009-12-18 PL PL09793543T patent/PL2379600T5/pl unknown
- 2009-12-18 RU RU2011129068/10A patent/RU2562114C2/ru active
- 2009-12-18 US US13/140,296 patent/US8361469B2/en active Active
- 2009-12-18 MX MX2011006501A patent/MX2011006501A/es active IP Right Grant
- 2009-12-18 CN CN200980157157.2A patent/CN102325795B/zh active Active
- 2009-12-18 DK DK09793543.1T patent/DK2379600T4/da active
- 2009-12-18 WO PCT/EP2009/067598 patent/WO2010072691A1/en not_active Ceased
- 2009-12-18 PT PT97935431T patent/PT2379600E/pt unknown
- 2009-12-18 ES ES09793543T patent/ES2458665T5/es active Active
- 2009-12-22 TW TW098144133A patent/TWI476003B/zh active
2011
- 2011-06-05 IL IL213356A patent/IL213356A/en active IP Right Grant
- 2011-06-22 ZA ZA2011/04599A patent/ZA201104599B/en unknown
2012
- 2012-12-20 US US13/721,755 patent/US9574011B2/en active Active
- 2012-12-20 US US13/721,802 patent/US8652471B2/en active Active
2015
- 2015-03-11 JP JP2015048157A patent/JP6114326B2/ja active Active
2017
- 2017-01-06 US US15/400,366 patent/US20170114147A1/en not_active Abandoned
2019
- 2019-03-25 US US16/363,327 patent/US20190211112A1/en not_active Abandoned
2024
- 2024-02-26 FR FR24C1008C patent/FR24C1008I1/fr active Active
- 2024-12-20 NL NL301310C patent/NL301310I2/nl unknown
2025
- 2025-02-25 NO NO2025013C patent/NO2025013I1/no unknown
- 2025-03-17 FI FIC20250014C patent/FIC20250014I1/fi unknown
- 2025-03-25 HU HUS2500017C patent/HUS2500017I1/hu unknown
- 2025-04-10 FR FR25C1014C patent/FR25C1014I1/fr active Active

Also Published As

Publication number	Publication date
PL2379600T5 (pl)	2021-03-08
JP2012513377A (ja)	2012-06-14
US20170114147A1 (en)	2017-04-27
DK2379600T3 (da)	2014-04-28
RU2011129068A (ru)	2013-01-27
CA2745317A1 (en)	2010-07-01
JP6114326B2 (ja)	2017-04-12
US20190211112A1 (en)	2019-07-11
FR25C1014I1 (fr)	2025-06-20
US20130251722A1 (en)	2013-09-26
KR101600308B1 (ko)	2016-03-07
IL213356A0 (en)	2011-07-31
EP3260466A1 (en)	2017-12-27
ES2458665T5 (es)	2021-06-30
DK2379600T4 (da)	2021-01-04
US9574011B2 (en)	2017-02-21
NL301310I2 (nl)	2025-02-11
FIC20250014I1 (fi)	2025-03-17
US20130251721A1 (en)	2013-09-26
KR20160031028A (ko)	2016-03-21
ES2458665T3 (es)	2014-05-06
KR101745394B1 (ko)	2017-06-09
HUS2500017I1 (hu)	2025-04-28
ES2458665T9 (en)	2025-04-22
BRPI0924058A2 (pt)	2019-10-15
US8652471B2 (en)	2014-02-18
WO2010072691A1 (en)	2010-07-01
CA2745317C (en)	2019-03-05
PL2379600T3 (pl)	2014-07-31
ZA201104599B (en)	2012-03-28
IL213356A (en)	2017-06-29
EP2379600B1 (en)	2014-01-22
EP2379600A1 (en)	2011-10-26
EP2379600B2 (en)	2020-10-14
AU2009331570A1 (en)	2011-06-30
US8361469B2 (en)	2013-01-29
EP2746294A2 (en)	2014-06-25
JP5714505B2 (ja)	2015-05-07
PT2379600E (pt)	2014-04-29
CN102325795A (zh)	2012-01-18
US20110318356A1 (en)	2011-12-29
AU2009331570C1 (en)	2024-04-18
CN102325795B (zh)	2015-03-25
MX2011006501A (es)	2011-07-12
BRPI0924058B1 (pt)	2021-08-17
RU2562114C2 (ru)	2015-09-10
EP2746294A3 (en)	2015-01-07
AU2009331570B2 (en)	2013-10-17
FR24C1008I1 (fr)	2024-04-19
JP2015178495A (ja)	2015-10-08
TWI476003B (zh)	2015-03-11
KR20110103432A (ko)	2011-09-20
TW201026330A (en)	2010-07-16

Publication	Publication Date	Title
FIC20250014I1 (fi)	2025-03-17	Konsitsumabi
DK2370462T3 (da)	2014-09-08	Glucagon-analoger
DK2342317T3 (da)	2013-03-18	Hængende-dråbe-plade
BRPI0907376A2 (pt)	2015-07-14	Fotobiorretador
EP2258938A4 (en)	2012-09-05	TYPE VEHICLE TO BE PROVIDED
EP2368526A4 (en)	2015-04-15	INSERTION TOOL FOR AN INTRAOCULAR LENS
BRPI0914649A2 (pt)	2015-07-07	Piprazolo-quinazolinas
EP2336764A4 (en)	2011-09-28	LIQUID CHROMATOGRAPH
DE602008003972D1 (de)	2011-01-27	Sitzrücklehnungsmechanismus
DE602008003521D1 (de)	2010-12-30	Sitzrücklehnungsmechanismus
DK2342454T3 (da)	2013-10-28	Vindkraftanlæg
DK2336132T3 (da)	2014-04-07	Morpholinpurinderivat
DK2335031T3 (da)	2019-08-26	In-line-måler
EP2368115A4 (en)	2012-08-22	ANALYTE DETECTION TEST
EP2308156A4 (en)	2014-02-19	STEP ACTUATOR
DK2379557T3 (da)	2012-12-17	Aminopyrazol-forbindelse
DK2271613T3 (da)	2014-07-14	Hydroxymethylcyklohexylaminer
DE602008003970D1 (de)	2011-01-27	Strahlstromkalibriersystem
EP2257170A4 (en)	2011-08-03	TETRAHYDROFUROPYRIDONE
EP2248964A4 (en)	2011-08-31	DRILLING / TERMINAL DEVICE
BRPI0907522A2 (pt)	2019-09-24	biarlamidas
DE112009000183A5 (de)	2011-02-03	Sicherheitsvorreiber
EP2339366A4 (en)	2013-01-30	DEVICE FOR OPTICAL DISTANCE MEASUREMENT
BRPI0909634A2 (pt)	2015-09-22	2-aminoquinolinas
DE602009000862D1 (de)	2011-04-28	Gehwagenbremse